Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stenting And Thrombectomy Systems Fuel Neuro Device Market Growth

Executive Summary

Advances in distally protected carotid artery stenting systems and second-generation cerebral thrombectomy devices will help drive strong growth in the US neurointerventional device market over the next five years. The market, which includes endovascular devices for the treatment of cerebral aneurysms, arteriovenous malformations, stroke, and carotid artery disease, is projected to grow at a compound annual rate of 6.5%, and reach more than $846 million by 2018.

You may also be interested in...



Beauty Without Microplastic: Consumer Expectations For Cosmetic Products May Have To Change

Kelly Dobos, a consultant, adjunct professor, and former president of the Society of Cosmetic Chemists, discusses the challenges facing beauty businesses and formulators, and the changes to cosmetic products that could be coming consumers’ way, under developing bans on microplastic use.

FDA Warns Eye Care Company Conducting Unapproved Clinical Trial Of Drug-Device Product

The FDA sent a warning letter to Arbor Center for EyeCare for failing to submit an IND before beginning a trial of a novel drug-device combination product.

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035827

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel